Iago Rodriguez-Lago
@iagorlago
Gastroenterologist, #IBD, espresso, Oasis, Sigur Rós
ID: 591214781
26-05-2012 20:11:55
2,2K Tweet
1,1K Followers
441 Following
Rincones con buenas vistas en Bilbao mirando a Universidad Deusto - Deustuko Unibertsitatea
If you want to know everything on #IBD patient empowerment in research and how to design a patient centered study with state-of-the-art monitoring, register to the #EpiCom workshop at next #ECCO congress! ecco-ibd.eu/discover-the-p… Sophie Restellini Iago Rodriguez-Lago Peter Bossuyt EFCCA
Podrían tratarse algunos pacientes con EII (refractaria) con terapias CAR-T? Ana Alfonso Piérola Paula Rodriguez-Otero
Ausencia de correlación entre el daño intestinal (indice de Lemann) y el grado de discapacidad en la enfermedad de Crohn - estudio CROCO Joana Torres Joana Branco Revés #ECCO2024
Empieza la LX edición del curso monográfico en EII para residentes de GETECCU Francisco Rodríguez-Moranta Triana IBD Mariam Aguas Raquel Vicente Daniel Carpio
‼️ Last paper from our group 👇 Patients with incidental IBD (asymptomatic) have a different exposure to heavy metals and trace elements. vs controls ⬆️ sodium, potassium, boron ⬇️ zinc, uranium, copper, germanium Manuel Barreiro OSIBarru-GaldakaoESI shorturl.at/lxJQV
🗓️💙 Desde GETECCU unimos fuerzas con ACCU ESPAÑA para una colaboración especial en el Día Mundial de la #EII. Así es cómo podéis participar y apoyar la iniciativa ➡️ geteccu.org/dia-mundial-de… #DíaMundialEII #SomosUno
‼️19, 20, 21 y 22 de mayo Resumen diario #DDW2024 Washington Moderan FMsro, Margalida Calafat Sard Ponentes Lucía Madero, María Algara, Eduard Brunet, Antonio Caballero GETECCU Patrocinado J&J Innovative Medicine España
Honoured to share the most recent evidence on ustekinumab and both Spanish and South African experience in IBD with amazing colleagues from South Africa Colin Rush Nnete Nimrod Mokhele IBD Africa at SAGES 2024 in Cape Town Thanks to Johnson & Johnson for this great opportunity, unique experience
Ulcerative colitis + LOR to ustekinumab (89% prior anti-TNF, 53% VDZ) ➡️ GMA combination can safely recapture the response ⬇️ clinical disease activity ⬇️Fcal 64% stop steroids Fiorella Cañete Silvia Eva Iglesias Flores Manuel Barreiro Daniel Ginard shorturl.at/FI0LT
Thank you to Sociedade Portuguesa de Gastrenterologia and Joana Torres for the invitation to speak about the evolving epidemiology of IBD. Great meeting and opportunity to discuss great topics with friends and colleagues.
Excited for the results of our latest study: ➡️Bowel damage in patients with preclinical CD vs. symptomatic CD 🟰 No differences in overall bowel damage 📈Higher colonic/rectum score in preclinical CD Manuel Barreiro OSIBarru-GaldakaoESI bit.ly/3Y9xZed